Zogenix (ZGNX)

[TRUISM]

Zogenix (ZGNX) PT Raised to $28 at Brean Capital; ZX008 Finally Being Appreciated
July 15, 2015 8:11 AM EDT
Click For Link



Brean Capital analyst Difei Yang reiterated a Buy rating and boosted his price target on Zogenix, Inc. (NASDAQ: ZGNX) to $28.00 (from $20.00), saying investors are finally beginning to appreciate ZX008.

Yang commented, "Zogenix shares have shown strength during the days leading up to yesterday's KOL investor breakfast day. We believe ZX008 has finally begun to be appreciated by investors. As we have have said before, we believe ZX008 for Dravet syndrome is potentially a more efficacious drug than the competing compound from GW Pharma.

Based on the detailed discussion from yesterday's KOL investor meeting, we revisited the assumptions used in the calculations for our TP and made two positive revisions. This leads us to increase our TP from $20 to $28."

Shares of Zogenix, Inc. closed at $17.69 yesterday.



Blessings to All

TRUTH